CAMBRIDGE, Mass.–(Business WIRE)–Cognito Therapeutics, a late-stage company revolutionary non-invasive optogenetics-based therapies for neurodegenerative health conditions, declared nowadays it will current a digital symposium featuring a panel of leading neuroscientists to explore neurophysiological markers in Alzheimer’s Sickness development, at the 2022 Alzheimer’s and Parkinson’s Diseases (Advertisement/PD) Meeting, held March 15 – 20, 2022, in Barcelona, Spain and on the net.
Aspects of the virtual symposium panel are down below:
Symposium title: Predicting Alzheimer’s Disorder Development with Neurophysiological Markers
Date/Time: Wednesday, March 16, 2022 – 4:15 to 5:15 pm Central European Time
Agenda: (in Central European Time)
Introduction (4:15-4:20 pm)
Mihály Hajós, PharmD, PhD
Cognito Therapeutics, Cambridge, MA, United States.
Amyloid-connected disruption of early visible processing in healthful growing old and
gentle cognitive impairment (4:20-4:35 pm)
Daniel C. Javitt, MD, PhD
Division of Experimental Therapeutics, Department of Psychiatry,
Columbia College Healthcare Middle, New York, United States.
Compromised Conduct and Gamma Ability All through Working Memory in Cognitively
Balanced People today with Irregular CSF Amyloid/Tau (4:35-4:50 pm)
Xianghong Arakaki, MD, PhD
Neurosciences, Huntington Clinical Exploration Institutes, Pasadena, CA, United States.
EEG predicts efficacy of non-invasive gamma sensory stimulation therapy in topics
with Alzheimer’s sickness (4:50-5:05 pm)
Aylin Cimenser, PhD
Cognito Therapeutics, Cambridge, MA, United States
Dialogue (5:05-5:15 pm)
All contributors
A replay of the symposium panel will be posted on Cognito’s web site at www.cognitotx.com.
About Cognito Therapeutics
Cognito Therapeutics is a pioneer in illness-modifying therapeutic interventions for neurodegenerative conditions and human cognitive functionality. The enterprise has accomplished numerous scientific scientific studies demonstrating its investigational therapeutic system has the probable to properly gradual or cease cognitive drop and loss of brain quantity in Alzheimer’s condition. Cognito has gained Fda Breakthrough Machine Designation for the remedy of Alzheimer’s ailment and expects to start off pivotal studies in 2022. The company’s technologies was dependent on revolutionary optogenetics investigate by scientific co-founders Professors Li-Huei Tsai and Ed Boyden at MIT. Cognito Therapeutics is primarily based in Cambridge, MA. For far more details, be sure to visit www.cognitotx.com. Stick to us on Twitter at @cognitotx.